CareLit · DOI-Nachweis · Pneumologie
Once-daily tiotropium Respimat add-on to ICS ± LABA improves control across asthma severities
DOI 10.1055/s-0035-1544685
Bibliografische Angaben
Nachweis in CareLit
Autor:innenO Schmidt, JM FitzGerald, H Kerstjens, P Paggiaro, K Ohta, M Ichinose, P Moroni-Zentgraf, M Engel, H Schmidt, E Bateman
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Tiotropium Respimat added to ICS±LABA has been investigated across asthma severities. We present ACQ-7 responses from six Phase III randomised, double-blind, placebo-controlled, parallel-group trials in patients with symptomatic asthma. Methods: Two 48-wk trials (PrimoTinA, NCT00772538/6984): 5µg added to ICS (≥800µg budesonide or equivalent [bud or eq])+LABA; two 24-wk trials (MezzoTinA, NCT01172808/282…
Zitieren
Zitierempfehlung
O Schmidt, JM FitzGerald, H Kerstjens, P Paggiaro, K Ohta, M Ichinose, P Moroni-Zentgraf, M Engel, H Schmidt, E Bateman (2015) Once-daily tiotropium Respimat add-on to ICS ± LABA improves control across asthma severities. Pneumologie (02). https://doi.org/10.1055/s-0035-1544685
Mit CareLit weiterarbeiten